0001213900-18-009608.txt : 20180725
0001213900-18-009608.hdr.sgml : 20180725
20180725092245
ACCESSION NUMBER: 0001213900-18-009608
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180702
FILED AS OF DATE: 20180725
DATE AS OF CHANGE: 20180725
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pearson Mark E.
CENTRAL INDEX KEY: 0001486558
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14778
FILM NUMBER: 18967818
MAIL ADDRESS:
STREET 1: 3031 TISCH WAY
STREET 2: SUITE 505
CITY: SAN JOSE
STATE: CA
ZIP: 95128
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLIGENIX, INC.
CENTRAL INDEX KEY: 0000812796
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 411505029
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 EMMONS DRIVE
STREET 2: SUITE B-10
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 609-538-8200
MAIL ADDRESS:
STREET 1: 29 EMMONS DRIVE
STREET 2: SUITE B-10
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: DOR BIOPHARMA INC
DATE OF NAME CHANGE: 20020329
FORMER COMPANY:
FORMER CONFORMED NAME: ENDOREX CORP
DATE OF NAME CHANGE: 19960916
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19920703
3
1
ownership.xml
OWNERSHIP DOCUMENT
X0206
3
2018-07-02
0
0000812796
SOLIGENIX, INC.
SNGX
0001486558
Pearson Mark E.
29 EMMONS DRIVE, SUITE B-10
PRINCETON
NJ
08540
1
0
1
0
COMMON STOCK
2330000
D
WARRANT (RIGHT TO BUY)
2.25
2018-07-02
2022-01-02
COMMON STOCK
932000
I
See footnote
The warrant currently is exercisable, subject to a blocker provision that prevents the holder from exercising the warrant if such holder would beneficially own in excess of 4.99% of the issuer's common stock following such exercise.
These securities are held by Altamont Pharmaceutical Holdings, LLC, a company for which the reporting person serves as general partner and chief executive officer. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or any other purpose.
/s/ Mark E. Pearson
2018-07-24